2024-10-11 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a leading pharmaceutical company developing and manufacturing a wide range of medicines.

**1. Performance Comparison:**

* **Cumulative Return (LLY):** 886.67%
* **Cumulative Return (VOO):** 134.82%
* **Return Difference:** 751.85%
* **Relative Divergence:** 90.97% 

LLY has significantly outperformed the S&P 500 (VOO) over the period considered. Its current relative divergence suggests it's performed well compared to its historical performance against VOO.

**2. Recent Price Movement:**

* **Closing Price:** 919.74
* **5-day Moving Average:** 900.91
* **20-day Moving Average:** 907.12
* **60-day Moving Average:** 893.54

The stock price is currently above its 5-day, 20-day, and 60-day moving averages, indicating a bullish trend.

**3. Technical Indicators:**

* **RSI:** 55.61
* **PPO:** 0.09
* **Delta_Previous_Relative_Divergence:** -2.73 
* **Expected_Return:** 42.4% 

The RSI suggests that the stock is in a moderately bullish territory. The PPO indicates a positive momentum. The negative Delta_Previous_Relative_Divergence suggests a slight short-term bearish trend. The Expected_Return is significant, suggesting potential for strong returns over the next five years, exceeding the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |

The company's most recent earnings report (2024-08-08) exceeded analysts' expectations with an EPS of 3.29 and revenue of $11.30B. The company's strong performance is driven by the continued success of its key products, particularly its diabetes drugs and a new Alzheimer's treatment. This positive trend is expected to continue, with analysts predicting continued growth in the coming quarters.

**5. News and Recent Issues:**

Recent market outlook for LLY is positive, with analysts attributing it to the strong performance of its new Alzheimer's treatment and promising pipeline. FINBOLD highlighted the company's successful earnings report, exceeding expectations, and its positive outlook for the future. 

**6. Overall Analysis:**

Eli Lilly and Co (LLY) has shown strong performance, exceeding the S&P 500 in cumulative returns. The stock is currently in a bullish trend, supported by recent earnings exceeding expectations and analysts' positive outlook.  The significant Expected_Return suggests LLY could continue to outperform the market. However, it's worth noting that the slight short-term bearish trend indicated by Delta_Previous_Relative_Divergence could influence short-term price movement. Overall, LLY appears to be a promising investment, with a strong track record and a promising future.

**7. Recommendation:**

Based on the analysis above, Eli Lilly and Co (LLY) is a good investment option for investors seeking long-term growth and potential for outperformance. The company's strong financial performance, positive outlook, and promising product pipeline make it a compelling choice. However, investors should consider the potential short-term bearish trend and adjust their investment strategy accordingly. 
